Transaction DateRecipientSharesTypePriceValue
3rd July 2020Anthony C. J. Fernando17,949Exercise of derivative$0.00
30th June 2020Richard C Jr Pfenniger3,125Grant/award etc.$0.00
30th June 2020Brett Farabaugh30,000Exercise of derivative$0.00
30th June 2020Richard C Jr Pfenniger2,403Grant/award etc.$0.00
8th June 2020Richard C Jr Pfenniger6,213Grant/award etc.$0.00
8th June 2020Paul A Laviolette22,500Grant/award etc.$0.00
8th June 2020Paul A Laviolette8,901Grant/award etc.$0.00
8th June 2020Jane Ph D Hsiao22,500Grant/award etc.$0.00
8th June 2020Jane Ph D Hsiao7,988Grant/award etc.$0.00
8th June 2020Richard C Jr Pfenniger22,500Grant/award etc.$0.00
Trans Enterix
Trans Enterix logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 2/10.

TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. The company was founded by William N. Starling in 2006.

Ticker: TRXC
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 876378
Employees: 163
Exchange: NYSE American
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $16 M (0%)
Inventory, Net: $11 M (0%)
Other Assets, Current: $7 M (-2%)
Assets, Current: $34 M (22%)
Property, Plant and Equipment, Net: $7 M (47%)
Other Assets, Noncurrent: $2 M (-23%)
Assets: $76 M (1%)
Accounts Payable, Current: $2 M (-34%)
Accrued Liabilities, Current: $7 M (-20%)
Liabilities, Current: $10 M (-22%)
Other Liabilities, Noncurrent: $1 M (-22%)
Liabilities: $16 M (-14%)
Common Stock, Value, Issued: $57 Th (171%)
Common Stock, Shares, Issued: $57 M (175%)
Additional Paid in Capital, Common Stock: $755 M (4%)
Retained Earnings (Accumulated Deficit): $694 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-6%)
Stockholders' Equity (Parent): $60 M (0%)
Liabilities and Equity: $76 M (1%)
Revenue: $655 Th (0%)
Cost of Revenue: $1 M (-55%)
Gross Margin: $758 Th (-60%)
Research and Development: $4 M (-48%)
Sales and Marketing: $3 M (-59%)
General and Administrative Expenses: $4 M (-48%)
Restructuring Charges: $858 Th (-90%)
Operating Income/Loss: $14 M (-54%)
Other Income, net: $165 Th (-46%)
Provision for income taxes: $691 Th (-50%)
EPS (basic): $0.27 (-64%)
EPS (diluted): $0.27 (-64%)